NCT04681768View on ClinicalTrials.gov

Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

January 20, 2025

Study Completion Date

April 1, 2025

Conditions
Breast Cancer/ Metastatic Breast Cancer
Interventions
DRUG

Abemaciclib

Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)

Trial Locations (1)

81675

Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, Munich

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Technical University of Munich

OTHER

NCT04681768 - Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter